Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Regeneron
Regeneron
Dupixent recaptures top Rx, OTC pharma brand spot in April
Medical Marketing and Media
Wed, 05/8/24 - 11:03 pm
DTC advertising
Dupixent
Sanofi
Regeneron
ASGCT24: Regeneron’s Gene Therapy Shows ‘Dramatic’ Hearing Improvement in Deaf Kids
BioSpace
Wed, 05/8/24 - 11:33 am
Regeneron
DB-OTO
genetic deafness
gene therapy
ASGCT
Regeneron, Lilly grapple with clinical endpoints as obesity space moves to improving weight loss
Fierce Biotech
Thu, 05/2/24 - 10:14 pm
Regeneron
Eli Lilly
Zepbound
obesity
trevogrumab
bimagrumab
Regeneron Misses Q1 Earnings on Lower-Than-Expected Eylea Sales
BioSpace
Thu, 05/2/24 - 10:10 pm
Regeneron
Eylea
earnings
Regeneron's blockbuster eye drug posts weaker sales due to inventory impact
Reuters
Thu, 05/2/24 - 11:26 am
Regeneron
earnings
Eylea
Dupixent’s DU More campaign breathes life into asthma treatment space
Medical Marketing and Media
Mon, 04/29/24 - 09:53 am
Dupixent
DTC advertising
Sanofi
Regeneron
AbbVie's Rinvoq conquers Regeneron and Sanofi's Dupixent in eczema trial—again
Fierce Pharma
Fri, 04/26/24 - 11:18 am
AbbVie
Rinvoq
Regeneron
Sanofi
Dupixent
atopic dermatitis
Regeneron expands in gene editing with Mammoth deal
BioPharma Dive
Thu, 04/25/24 - 11:31 am
Regeneron
Mammoth Biosciences
CRISPR
gene editing
Regeneron to defend against DOJ complaint on drug-price manipulation
Yahoo/Reuters
Tue, 04/16/24 - 10:02 pm
Regeneron
DOJ
drug pricing
Eylea
Regeneron builds new venture arm with $500M commitment to invest in biotech and beyond
Fierce Biotech
Mon, 04/15/24 - 11:04 am
Regeneron
funding
venture capital
biotech
DOJ Sues Regeneron for Allegedly Inflating Medicare Pricing for Eye Drug Eylea
BioSpace
Thu, 04/11/24 - 11:27 am
DOJ
Regeneron
Medicare
Eylea
drug pricing
False Claims Act
COPD Market Poised for ‘Paradigm Shift’ with Potential Approvals in 2024
BioSpace
Wed, 03/27/24 - 11:06 am
COPD
Sanofi
Regeneron
Verona Pharma
Dupixent
ensifentrine
FDA blocks approval of Regeneron's blood cancer drug over confirmatory trial enrollment
Fierce Biotech
Mon, 03/25/24 - 11:27 am
Regeneron
FDA
odronextamab
clinical trials
blood cancers
After decades of waiting, late-stage therapies may penetrate the COPD market this year
Clinical Trials Arena
Sun, 03/24/24 - 10:31 pm
COPD
drug development
Sanofi
Regeneron
Dupixent
Verona
ensifentrine
Innovent's anti-VEGF drug matches Eylea in phase 2 eye disease trial
Fierce Biotech
Tue, 03/19/24 - 11:21 am
Innovent
Regeneron
Bayer
anti-VEGF
neovascular age-related macular degeneration
IBI302
Eylea
US appeals court revives Regeneron's antitrust lawsuit against Novartis
Yahoo/Reuters
Mon, 03/18/24 - 05:09 pm
Novartis
Regeneron
legal
Eylea
Lucentis
antitrust
Incyte, itching for a piece of Dupixent's market, hits goals in midphase skin disease trial
Fierce Biotech
Mon, 03/11/24 - 11:52 am
Incyte
clinical trials
prurigo nodularis
povorcitinib
Dupixent
Sanofi
Regeneron
Sanofi, Regeneron Secure FDA Priority Review for Dupixent in COPD
BioSpace
Fri, 02/23/24 - 10:43 am
FDA
Sanofi
Regeneron
Dupixent
priority review
COPD
Regeneron Looks to Target Weight Loss Market with Muscle-Preserving Antibodies
BioSpace
Mon, 02/5/24 - 10:20 am
Regeneron
obesity
muscle
drug development
2seventy bio to sell experimental cell therapies, names new CEO
Reuters
Tue, 01/30/24 - 10:23 am
2seventy bio
Regeneron
Abecma
cell therapy
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »